VivoSeq
Oncology

Mantle Cell Lymphoma

163

Pipeline Programs↗

84

Active Trials↗

65

Companies Involved↗

Mantle Cell Lymphoma is a highly competitive landscape with 163 programs across 65 companies. The most active players are Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., TG Therapeutics, Inc., Zhejiang DTRM Biopharma. 12 therapies are approved with 22 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

80/100

Pipeline Velocity

42/100

Mech. Concentration

6/100

Completion Rate

76/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

3 programs

Phase 1T

TG Therapeutics, Inc.

2 programs

Phase 1Z

Zhejiang DTRM Biopharma

1 program

Phase 1Genmab logo

Genmab

1 program

Phase 1Novartis logo

Novartis

4 programs

Phase 2Sanofi logo

Sanofi

3 programs

Phase 2

Pipeline

Programs by Phase

Preclinical9

Brexucabtagene Autoleucel

Gilead

Curcumin

Merck & Co.

Lisocabtagene Maraleucel

Bristol-Myers Squibb

Bendamustine Hydrochloride

SymBio Pharmaceuticals

Axitinib

Prism Pharmaceuticals

Phase 117

Idelalisib

Gilead

Epcoritamab

Genmab

Panobinostat

SecuraBio

Ublituximab

TG Therapeutics, Inc.

Gemcitabine

Johnson & Johnson

Phase 2103

Axicabtagene Ciloleucel

Gilead

Abemaciclib

Eli Lilly

Polatuzumab Vedotin

Roche

Glofitamab

Roche

Antineoplaston A10

Burzynski Research Institute

Phase 322

Zanubrutinib

BeOne Medicines

Parsaclisib

Incyte

Venetoclax

AbbVie

Orelabrutinib

Beijing InnoCare Pharma Tech Co., Ltd.

Ibrutinib

Pharmacyclics LLC.

Approved12

Cyclophosphamide

Baxter Healthcare Corporation

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Dexamethasone

Aspen Global Incorporated

Prednisone

Roxane Laboratories

Cytarabine

Teva

Analysis

Modality Breakdown

81%

Small molecule

143 of 177 classified programs — the dominant modality here.

19%ALL OTHERSMonoclonal antibody169%Cell therapy106%Protein / enzyme42%Antibody–drug conjugate21%Vaccine1<1%Radiopharmaceutical1<1%

Small molecule leads; the ring shows all 177 classified programs, each share of the total. Modality classified for 97% of 190 pipeline programs.

Analysis

Trial Status

256

clinical trials

Completed113 · 44%
Recruiting43 · 17%
Active, not recruiting31 · 12%
Terminated26 · 10%
Unknown status22 · 9%
Not yet recruiting10 · 4%
Other11 · 4%

Clinical Trials

Trial Activity

256 trials

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Recruiting·PPeking University Third Hospital·Phase 2·NCT07460362·43 enrolled
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06504199·39 enrolled
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Recruiting·—·Phase 2·NCT05910801·100 enrolled
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06263491·50 enrolled
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 2·NCT07082686·68 enrolled
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
Recruiting·UUniversity College, London·Phase 2·NCT05635162·50 enrolled
A Clinical Study of Hanlikang and BTK Inhibitors in the Treatment of Newly Diagnosed Mantle Cell Lymphoma
Recruiting·ZZhengzhou University·N/A·NCT05506410·100 enrolled
Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma
Recruiting·PPeking University Third Hospital·N/A·NCT07257510·34 enrolled
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Recruiting·UUniversity of California, San Francisco·Phase 2·NCT06252675·30 enrolled
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
Recruiting·AAustralasian Leukaemia and Lymphoma Group·Phase 2·NCT05833763·42 enrolled
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Recruiting·BBeijing InnoCare Pharma Tech Co., Ltd.·Phase 3·NCT05051891·356 enrolled
Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)
Recruiting·—·Phase 2·NCT03616782·98 enrolled
Clinical Trial to Evaluate the Efficacy and Safety of Pirtobrutinib With Rituximab in Patients With Mantle Cell Lymphoma
Recruiting·GGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea·Phase 2·NCT07285590·50 enrolled
Ultra Low Dose Radiation Delivered Before or After Chemotherapy-Free Targeted Therapy in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04054167·80 enrolled
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Recruiting·—·Phase 2·NCT06054776·40 enrolled
Page 1 of 18

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)